Neuronal Activation in the Central Nervous System of Rats in the Initial Stage of Chronic Kidney Disease-Modulatory Effects of Losartan and Moxonidine

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Palkovits, Miklós ^a   Šebeková, Katarína ^b   Klenovics, Kristina Simon ^b   Kebis, Anton ^c   Fazeli, Gholamreza ^d   Bahner, Udo ^e   Heidland, August ^d  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b Physics and Informatics   (Slovakia)

^c SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e KfH Kidney Centre   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LOSARTAN; MOXONIDINE; PLACEBO; PROTEIN C FOS;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN NERVE CELL; BRAIN REGION; BRAIN SLICE; CENTRAL NERVOUS SYSTEM; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DORSAL RAPHE NUCLEUS; DRUG EFFECT; HISTAMINERGIC SYSTEM; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; HYPOTHALAMUS; LIMBIC SYSTEM; LOCUS CERULEUS; MALE; MONOAMINERGIC SYSTEM; NERVE STIMULATION; NONHUMAN; NORADRENERGIC NERVE; PAIN; RAT; SEROTONINERGIC NERVE CELL; THALAMUS; TUBEROMAMILLARY NUCLEUS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BRAIN; CENTRAL NERVOUS SYSTEM; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; KIDNEY; LOCUS COERULEUS; LOSARTAN; MALE; NEPHRECTOMY; NEURONS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, WISTAR; RENAL INSUFFICIENCY, CHRONIC;

RATTUS;

EID: 84879251057     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066543     Document Type: Article

References (96)

1. Brouns R, De Deyn PP, (2004) Neurological complications in renal failure: a review. Clin Neurol Neurosurg 107: 1-16.
2. Seifter JL, Samuels MA, (2011) Uremic encephalopathy and other brain disorders associated with renal failure. Semin Neurol 31: 139-143.
3. Murray AM, Tupper DE, Knopman DS, Gilbertson DT, Pederson SL, et al. (2006) Cognitive impairment in hemodialysis patients is common. Neurology 67: 216-223.
4. Lux S, Mirzazade S, Kuzmanovic B, Plewan T, Eickhoff SB, et al. (2010) Differential activation of memory-relevant brain regions during a dialysis cycle. Kidney International 78: 794-802.
5. Davison SN, (2005) Chronic pain in end-stage renal disease. Adv Chronic Kidney Dis 12: 326-334.
6. Cohen SD, Patel SS, Khetpal P, Peterson RA, Kimmel PL, (2007) Pain, sleep disturbance, and quality of life in patients with chronic kidney disease. Clin J Am Soc Nephrol 2: 919-925.
7. Parker KP, (2003) Sleep disturbances in dialysis patients. Sleep Med Rev 7: 131-143.
8. Hedayati SS, Bosworth HB, Kuchibhatla M, Kimmel PL, Szczech LA, (2006) The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney Int 69: 1662-1668.
9. Riezebos RK, Nauta KJ, Honig A, Dekker FW, Siegert CE The association of depressive symptoms with survival in a Dutch cohort of patients with end-stage renal disease. Nephrol Dial Transplant 25: 231-236.
10. Spiegel BM, Melmed G, Robbins S, Esrailian E, (2008) Biomarkers and health-related quality of life in end-stage renal disease: a systematic review. Clin J Am Soc Nephrol 3: 1759-1768.
11. Vanholder R, Van Laecke S, Glorieux G, (2008) What is new in uremic toxicity? Pediatr Nephrol 23: 1211-1221.
12. Rabbani N, Sebekova K, Sebekova K Jr, Heidland A, Thornalley PJ, (2007) Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function. Kidney Int 72: 1113-1121.
13. Loske C, Neumann A, Cunningham AM, Nichol K, Schinzel R, et al. (1998) Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress. J Neural Transm 105: 1005-1015.
14. Niiya Y, Abumiya T, Shichinohe H, Kuroda S, Kikuchi S, et al. (2006) Susceptibility of brain microvascular endothelial cells to advanced glycation end products-induced tissue factor upregulation is associated with intracellular reactive oxygen species. Brain Res 1108: 179-187.
15. Selley ML, (2003) Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging 24: 903-907.
16. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, et al. (2005) Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 16: 2456-2461.
17. Kelly KJ, (2003) Distant effects of experimental renal ischemia/reperfusion injury. J Am Soc Nephrol 14: 1549-1558.
18. Vanholder R, De Deyn PP, Van Biesen W, Lameire N, (2008) Marconi revisited: from kidney to brain-two organ systems communicating at long distance. J Am Soc Nephrol 19: 1253-1255.
19. Hirotsu C, Tufik S, Ribeiro DA, Alvarenga TA, Andersen ML, (2011) Genomic damage in the progression of chronic kidney disease in rats. Brain Behav Immun 25: 416-422.
20. Orth SR, Amann K, Strojek K, Ritz E, (2001) Sympathetic overactivity and arterial hypertension in renal failure. Nephrol Dial Transplant 16Suppl 1: 67-69.
21. Koomans HA, Blankestijn PJ, Joles JA, (2004) Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 15: 524-537.
22. Bigazzi R, Kogosov E, Campese VM, (1994) Altered norepinephrine turnover in the brain of rats with chronic renal failure. J Am Soc Nephrol 4: 1901-1907.
23. Reid IA, (1992) Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 262: E763-778.
24. Grassi G, Seravalle G, Ghiadoni L, Tripepi G, Bruno RM, et al. (2011) Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clin J Am Soc Nephrol 6: 2620-2627.
25. Campese VM, Ye S, Zhong H, Yanamadala V, Ye Z, et al. (2004) Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol 287: H695-703.
26. Palkovits M, Sebekova K, Gallatz K, Boor P, Sebekova K Jr, et al. (2009) Neuronal activation in the CNS during different forms of acute renal failure in rats. Neuroscience 159: 862-882.
27. Hailpern SM, Melamed ML, Cohen HW, Hostetter TH, (2007) Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 18: 2205-2213.
28. Elias MF, Elias PK, Seliger SL, Narsipur SS, Dore GA, et al. (2009) Chronic kidney disease, creatinine and cognitive functioning. Nephrol Dial Transplant 24: 2446-2452.
29. Buchman AS, Tanne D, Boyle PA, Shah RC, Leurgans SE, et al. (2009) Kidney function is associated with the rate of cognitive decline in the elderly. Neurology 73: 920-927.
30. Iliescu EA, Yeates KE, Holland DC, (2004) Quality of sleep in patients with chronic kidney disease. Nephrol Dial Transplant 19: 95-99.
31. De Santo RM, Bilancio G, Santoro D, Vecchi ML, Perna A, et al. (2011) A longitudinal study of sleep disorders in early-stage chronic kidney disease. J Ren Nutr 20: S59-63.
32. Sim JJ, Rasgon SA, Kujubu DA, Kumar VA, Liu IL, et al. (2009) Sleep apnea in early and advanced chronic kidney disease: Kaiser Permanente Southern California cohort. Chest 135: 710-716.
33. Joosten H, Izaks GJ, Slaets JP, de Jong PE, Visser ST, et al. (2011) Association of cognitive function with albuminuria and eGFR in the general population. Clin J Am Soc Nephrol 6: 1400-1409.
34. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, et al. (2011) Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 57: 846-851.
35. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubina P, Lahera V, et al. (2008) Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl: S4-9.
36. Krivosikova Z, Sebekova K, Spustova V, Lajdova I, Dzurik R, (1999) Enalapril in subantihypertensive dosage attenuates kidney proliferation and functional recovery in normotensive ablation nephropathy of the rat. Physiol Res 48: 429-435.
37. Morgan JI, Curran T, (1991) Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci 14: 421-451.
38. Herdegen T, Leah JD, (1998) Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res Brain Res Rev 28: 370-490.
39. Abbadie C, Besson JM, (1992) c-fos expression in rat lumbar spinal cord during the development of adjuvant-induced arthritis. Neuroscience 48: 985-993.
40. Stamp JA, Herbert J, (1999) Multiple immediate-early gene expression during physiological and endocrine adaptation to repeated stress. Neuroscience 94: 1313-1322.
41. Hebert MA, Serova LI, Sabban EL, (2005) Single and repeated immobilization stress differentially trigger induction and phosphorylation of several transcription factors and mitogen-activated protein kinases in the rat locus coeruleus. J Neurochem 95: 484-498.
42. Timofeeva E, Richard D, (2001) Activation of the central nervous system in obese Zucker rats during food deprivation. J Comp Neurol 441: 71-89.
43. Konsman JP, Blomqvist A, (2005) Forebrain patterns of c-Fos and FosB induction during cancer-associated anorexia-cachexia in rat. Eur J Neurosci 21: 2752-2766.
44. Muders F, Palkovits M, Bahner U, Kirst I, Elsner D, et al. (2001) Central inhibition of AT1receptors by eprosartan-in vitro autoradiography in the brain. Pharmacol Res 43: 251-255.
45. Campese VM, Ye S, Truong RH, Gamburd M, (2000) Losartan reduces sympathetic nerve outflow from the brain of rats with chronic renal failure. J Renin Angiotensin Aldosterone Syst 1: 202-208.
46. Ye S, Zhong H, Duong VN, Campese VM, (2002) Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. Hypertension 39: 1101-1106.
47. Amann K, Nichols C, Tornig J, Schwarz U, Zeier M, et al. (1996) Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 11: 1003-1011.
48. Prichard BN, Graham BR, Owens CW (1999) Moxonidine: a new antiadrenergic antihypertensive agent. J Hypertens Suppl 17: S41-54.
49. Ernsberger P, (2000) Pharmacology of moxonidine: an I1-imidazoline receptor agonist. J Cardiovasc Pharmacol 35: S27-41.
50. Morrison AB, (1962) Experimentally induced chronic renal insufficiency in the rat. Laboratory Investigation 11: 321-332.
51. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, et al. (2000) Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 11: 1469-1478.
52. Sebekova K, Schinzel R, Munch G, Krivosikova Z, Dzurik R, et al. (1999) Advanced glycation end-product levels in subtotally nephrectomized rats: beneficial effects of angiotensin II receptor 1 antagonist losartan. Miner Electrolyte Metab 25: 380-383.
53. Munch G, Keis R, Wessels A, Riederer P, Bahner U, et al. (1997) Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 35: 669-677.
54. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillere-Blandin C, Nguyen AT, et al. (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161: 2524-2532.
55. Kurella Tamura M, Muntner P, Wadley V, Cushman M, Zakai NA, et al. (2011) Albuminuria, kidney function, and the incidence of cognitive impairment among adults in the United States. Am J Kidney Dis 58: 756-763.
56. Benarroch EE, (2009) The locus ceruleus norepinephrine system: functional organization and potential clinical significance. Neurology 73: 1699-1704.
57. Ye S, Ozgur B, Campese VM, (1997) Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney International 51: 722-727.
58. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, et al. (1992) Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327: 1912-1918.
59. Campese VM, Kogosov E, Koss M, (1995) Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 26: 861-865.
60. Neumann J, Ligtenberg G, Klein, II, Koomans HA, Blankestijn PJ, (2004) Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney International 65: 1568-1576.
61. Casper RC, (1998) Depression and eating disorders. Depress Anxiety 8Suppl 1: 96-104.
62. Jellinger K, Riederer P, (1977) Brain monoamines in metabolic (endotoxic) coma. A preliminary biochemical study in human postmortem material. J Neural Transm 41: 275-286.
63. Siassi F, Wang M, Kopple JD, Swendseid ME, (1977) Brain serotonin turnover in chronically uremic rats. Am J Physiol 232: E526-528.
64. Aguilera A, Selgas R, Codoceo R, Bajo A, (2000) Uremic anorexia: a consequence of persistently high brain serotonin levels? The tryptophan/serotonin disorder hypothesis. Perit Dial Int 20: 810-816.
65. Haas H, Panula P, (2003) The role of histamine and the tuberomamillary nucleus in the nervous system. Nature Reviews Neuroscience 4: 121-130.
66. Schmid G, Przuntek H, Fricke L, Heidland A, Hempel K, (1978) Increased histidine and histamine content in the brain of chronic uremic rats. Cause of enhanced cerebral cyclic adenosine monophosphate in uremia? Am J Clin Nutr 31: 1665-1668.
67. Jeppsson B, Freund HR, Gimmon Z, James JH, von Meyenfeldt MF, et al. (1982) Blood-brain barrier derangement in uremic encephalopathy. Surgery 92: 30-35.
68. Geiger H, Bahner U, Palkovits M, Hugo C, Niklas E, et al. (1989) Atrial natriuretic peptide in brain preoptic areas: implications for fluid and salt homeostasis. J Cardiovasc Pharmacol 13Suppl 6: S20-23.
69. Geiger H, Bahner U, Kraus I, Hoffmann M, Palkovits M, et al. (1993) Effect of ACE inhibitors on atrial natriuretic factor in the brains of rats with reduced renal mass. Kidney International 44: 24-29.
70. Seliger SL, Katzel LI, Fink JC, Weir MR, Waldstein SR, (2008) Renal function and cardiovascular response to mental stress. Am J Nephrol 28: 304-310.
71. Imbe H, Iwai-Liao Y, Senba E, (2006) Stress-induced hyperalgesia: animal models and putative mechanisms. Front Biosci 11: 2179-2192.
72. Miller EK, Cohen JD, (2001) An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24: 167-202.
73. Gianaros PJ, Onyewuenyi IC, Sheu LK, Christie IC, Critchley HD, (2012) Brain systems for baroreflex suppression during stress in humans. Hum Brain Mapp 33: 1700-1716.
74. Bernhardt BC, Singer T, (2012) The neural basis of empathy. Annu Rev Neurosci 35: 1-23.
75. Armstrong JE, Laing DG, Wilkes FJ, Kainer G, (2010) Smell and taste function in children with chronic kidney disease. Pediatr Nephrol 25: 1497-1504.
76. Griep MI, Van der Niepen P, Sennesael JJ, Mets TF, Massart DL, et al. (1997) Odour perception in chronic renal disease. Nephrol Dial Transplant 12: 2093-2098.
77. Landis BN, Marangon N, Saudan P, Hugentobler M, Giger R, et al. (2011) Olfactory function improves following hemodialysis. Kidney International 80: 886-893.
78. Bomback AS, Raff AC, (2011) Olfactory function in dialysis patients: a potential key to understanding the uremic state. Kidney International 80: 803-805.
79. Bossola M, Tazza L, Giungi S, Luciani G, (2006) Anorexia in hemodialysis patients: an update. Kidney International 70: 417-422.
80. Neil MJ, (2011) Clonidine: clinical pharmacology and therapeutic use in pain management. Curr Clin Pharmacol 6: 280-287.
81. Mukaddam-Daher S, Gutkowska J, (2000) Atrial natriuretic peptide is involved in renal actions of moxonidine. Hypertension 35: 1215-1220.
82. Kotanko P, (2006) Cause and consequences of sympathetic hyperactivity in chronic kidney disease. Blood Purif 24: 95-99.
83. Averill DB, Tsuchihashi T, Khosla MC, Ferrario CM, (1994) Losartan, nonpeptide angiotensin II-type 1 (AT1) receptor antagonist, attenuates pressor and sympathoexcitatory responses evoked by angiotensin II and L-glutamate in rostral ventrolateral medulla. Brain Res 665: 245-252.
84. Guasti L, Zanotta D, Diolisi A, Garganico D, Simoni C, et al. (2002) Changes in pain perception during treatment with angiotensin converting enzyme-inhibitors and angiotensin II type 1 receptor blockade. J Hypertens 20: 485-491.
85. Barzilay JI, Gao P, O'Donnell M, Mann JF, Anderson C, et al. (2011) Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies. Arch Intern Med 171: 142-150.
86. Sajjad I, Grodstein F, Kang JH, Curhan GC, Lin J, (2012) Kidney dysfunction and cognitive decline in women. Clin J Am Soc Nephrol 7: 437-443.
87. Abdelhafiz AH, Ahmed S, El Nahas M, (2011) Microalbuminuria: marker or maker of cardiovascular disease. Nephron Exp Nephrol. 119Suppl 1: e6-10.
88. Wada M, Nagasawa H, Iseki C, Takahashi Y, Sato H, et al. (2008) Cerebral small vessel disease and chronic kidney disease (CKD): results of a cross-sectional study in community-based Japanese elderly. J Neurol Sci. 15 272(1-2): 36-42.
89. Knopman DS (2010) Invited commentary: Albuminuria and microvascular disease of the brain-a shared pathophysiology. Am J Epidemiol 171: 287-289; author reply 290-281.
90. Weiner DE, Bartolomei K, Scott T, Price LL, Griffith JL, et al. (2009) Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. Am J Kidney Dis 53: 438-447.
91. Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, et al. (2009) Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med 169: 1195-1202.
92. Asif M, Soiza RL, McEvoy M, Mangoni AA (2012) Asymmetric Dimethylarginine: a Possible Link between Vascular Disease and Dementia. Curr Alzheimer Res.
93. Augustyniak RA, Victor RG, Morgan DA, Zhang W, (2006) L-NAME- and ADMA-induced sympathetic neural activation in conscious rats. Am J Physiol Regul Integr Comp Physiol 290: R726-732.
94. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, et al. (2006) ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37: 2024-2029.
95. Pikula A, Boger RH, Beiser AS, Maas R, DeCarli C, et al. (2009) Association of plasma ADMA levels with MRI markers of vascular brain injury: Framingham offspring study. Stroke 40: 2959-2964.
96. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Cayci T, et al. (2010) Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway? Nephrol Dial Transplant 25: 3250-3256.